PHARMACEUTICAL 2012

ELI Lilly Co
Rank 102 of 196



PHARMACEUTICAL 2012

ELI Lilly Co
Rank 102 of 196

The relative strengths and weaknesses of ELI Lilly Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ELI Lilly Co compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 76% points.The greatest weakness of ELI Lilly Co is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 81% points.

The company's Economic Capital Ratio, given in the ranking table, is 248%, being 14% points above the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	14,248,200
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	8,930,900
Liabilities, Non-Current	11,193,300
Other Assets	11,651,300
Other Compr. Net Income	-1,188,500
Other Expenses	7,038,100
Other Liabilities	0
Other Net Income	0
Other Revenues	24,286,500
Property and Equipment	7,760,300
Research and Development	5,020,800
Selling, General and Administrative Expense	7,879,900

Output Variable	Value in 1000 USD
Assets	33,659,800
Liabilities	20,124,200
Expenses	19,938,800
Revenues	24,286,500
Stockholders Equity	13,535,600
Net Income	4,347,700
Comprehensive Net Income	3,753,450
BaseVar	49,598,900
ECR before LimitedLiability	124%
Economic Capital Ratio	248%